Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.
The iron chelator deferoxamine and the polyamine biosynthesis inhibitor eflornithine (DL-alpha-difluoromethylornithine) were examined for anti-Pneumocystis carinii activity in the rat model of P. carinii pneumonia. The activity of deferoxamine at 250, 500, and 1,000 mg/kg given intraperitoneally provides evidence that iron chelation is a promising novel approach to P. carinii chemotherapy. Results with eflornithine at 2, 3, and 4% in drinking water confirm and extend previously reported activity in the rat model.
Clarkson
A B
AB
Department of Medical and Molecular Parasitology, New York University Medical Center, New York 10016.
Sarić
M
M
Grady
R W
RW
D000818:Animals; D003676:Deferoxamine / Q000627:therapeutic use*; D004195:Disease Models, Animal; D000518:Eflornithine / Q000627:therapeutic use*; D005260:Female; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D011897:Random Allocation; D051381:Rats; D011919:Rats, Inbred Strains; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003676:Deferoxamine; D000518:Eflornithine